Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells

Ryuji Ikeda; Lee C. Vermeulen; Elim Lau; Zhisheng Jiang; Marcia Pomplun; Jill M. Kolesar

doi:10.3892/mmr.2010.366

Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells

Ryuji Ikeda, Lee C. Vermeulen, Elim Lau, Zhisheng Jiang, Marcia Pomplun, Jill M. Kolesar

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Irinotecan (CTP-11) is a topoisomerase I inhibitor used in the treatment of colorectal cancer and non-small cell lung cancer (NSCLC). Despite an initial response to therapy, resistance to irinotecan reduces its efficacy. We isolated irinotecan-resistant human NSCLC A549 cells, termed A549/CTP-11R cells. A549/CTP-11R cells were resistant to irinotecan, as well as paclitaxel, gemcitabine and carboplatin. Curcumin, a nuclear factor-κB (NF-κB) inhibitor, increased the sensitivity to irinotecan of A549/CTP-11R cells. The expression level of Bcl-X_L and X-linked inhibitor of apoptosis protein, target genes of NF-κB, in A549/CTP-11R cells was higher than that in A549 cells. Our result suggests that the addition of curcumin to irinotecan reverses irinotecan resistance in NSCLC.

Original language	English
Pages (from-to)	1031-1034
Number of pages	4
Journal	Molecular Medicine Reports
Volume	3
Issue number	6
DOIs	https://doi.org/10.3892/mmr.2010.366
State	Published - Nov 2010

Keywords

Bcl-X
Curcumin
Irinotecan
Non-small cell lung cancer
X-linked inhibitor of apoptosis protein

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Genetics
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3892/mmr.2010.366

Cite this

@article{cb4a4a52aa3e4e1e9539b5bdacbfa253,

title = "Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells",

abstract = "Irinotecan (CTP-11) is a topoisomerase I inhibitor used in the treatment of colorectal cancer and non-small cell lung cancer (NSCLC). Despite an initial response to therapy, resistance to irinotecan reduces its efficacy. We isolated irinotecan-resistant human NSCLC A549 cells, termed A549/CTP-11R cells. A549/CTP-11R cells were resistant to irinotecan, as well as paclitaxel, gemcitabine and carboplatin. Curcumin, a nuclear factor-κB (NF-κB) inhibitor, increased the sensitivity to irinotecan of A549/CTP-11R cells. The expression level of Bcl-XL and X-linked inhibitor of apoptosis protein, target genes of NF-κB, in A549/CTP-11R cells was higher than that in A549 cells. Our result suggests that the addition of curcumin to irinotecan reverses irinotecan resistance in NSCLC.",

keywords = "Bcl-X, Curcumin, Irinotecan, Non-small cell lung cancer, X-linked inhibitor of apoptosis protein",

author = "Ryuji Ikeda and Vermeulen, {Lee C.} and Elim Lau and Zhisheng Jiang and Marcia Pomplun and Kolesar, {Jill M.}",

year = "2010",

month = nov,

doi = "10.3892/mmr.2010.366",

language = "English",

volume = "3",

pages = "1031--1034",

number = "6",

}

TY - JOUR

T1 - Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells

AU - Ikeda, Ryuji

AU - Vermeulen, Lee C.

AU - Lau, Elim

AU - Jiang, Zhisheng

AU - Pomplun, Marcia

AU - Kolesar, Jill M.

PY - 2010/11

Y1 - 2010/11

N2 - Irinotecan (CTP-11) is a topoisomerase I inhibitor used in the treatment of colorectal cancer and non-small cell lung cancer (NSCLC). Despite an initial response to therapy, resistance to irinotecan reduces its efficacy. We isolated irinotecan-resistant human NSCLC A549 cells, termed A549/CTP-11R cells. A549/CTP-11R cells were resistant to irinotecan, as well as paclitaxel, gemcitabine and carboplatin. Curcumin, a nuclear factor-κB (NF-κB) inhibitor, increased the sensitivity to irinotecan of A549/CTP-11R cells. The expression level of Bcl-XL and X-linked inhibitor of apoptosis protein, target genes of NF-κB, in A549/CTP-11R cells was higher than that in A549 cells. Our result suggests that the addition of curcumin to irinotecan reverses irinotecan resistance in NSCLC.

AB - Irinotecan (CTP-11) is a topoisomerase I inhibitor used in the treatment of colorectal cancer and non-small cell lung cancer (NSCLC). Despite an initial response to therapy, resistance to irinotecan reduces its efficacy. We isolated irinotecan-resistant human NSCLC A549 cells, termed A549/CTP-11R cells. A549/CTP-11R cells were resistant to irinotecan, as well as paclitaxel, gemcitabine and carboplatin. Curcumin, a nuclear factor-κB (NF-κB) inhibitor, increased the sensitivity to irinotecan of A549/CTP-11R cells. The expression level of Bcl-XL and X-linked inhibitor of apoptosis protein, target genes of NF-κB, in A549/CTP-11R cells was higher than that in A549 cells. Our result suggests that the addition of curcumin to irinotecan reverses irinotecan resistance in NSCLC.

KW - Bcl-X

KW - Curcumin

KW - Irinotecan

KW - Non-small cell lung cancer

KW - X-linked inhibitor of apoptosis protein

UR - http://www.scopus.com/inward/record.url?scp=78649462719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649462719&partnerID=8YFLogxK

U2 - 10.3892/mmr.2010.366

DO - 10.3892/mmr.2010.366

M3 - Article

C2 - 21472350

AN - SCOPUS:78649462719

SN - 1791-2997

VL - 3

SP - 1031

EP - 1034

JO - Molecular Medicine Reports

JF - Molecular Medicine Reports

IS - 6

ER -

Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this